The purpose of this email is to inform VFC-enrolled providers that the RSV monoclonal antibody product clesrovimab (trade name ENFLONSIA™ manufactured by Merck) is now available for ordering. VFC doses will begin shipping after Oct. 2, 2025.
Clesrovimab Use
Clesrovimab is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants under 8 months of age who are born during or entering their first RSV season and who are not protected through maternal RSV vaccination.
Administration Timing
Clesrovimab is a single 105 mg dose administered intramuscularly (IM) within one week after birth, ideally during the birth hospitalization prior to discharge. The dose size is the same for all infants. The timing of clesrovimab is seasonal. Eligible infants born outside the seasonal administration window (i.e., during April–September) who have not yet received a recommended dose should receive RSV antibody at the earliest opportunity beginning in October to optimize protection during the peak of the RSV season.
Providers should follow CDC’s recommended start and end dates for RSV product administration during the 2025–26 season: October 1, 2025 – March 31, 2026. Clesrovimab is expected to provide protection against RSV for the duration of the RSV season.
Please review ACIP’s recommendations, including the MMWR on use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus (PDF), as well as the package insert (PDF) for more information.
VFC Eligibility
Doses obtained through the North Carolina Immunization Program (NCIP) are for VFC-eligible children only. Non-eligible children must receive privately purchased clesrovimab.
Order Clesrovimab Here
Ordering Considerations
- Submit an order request for VFC doses to cover a two-week period of RSV season using the RSV Order Request Form.
- All requests will be reviewed and approved on a biweekly cadence.
- Orders will be cut off and reviewed at 9:00 am every other Monday.
- The first orders will be processed on October 2, 2025.
- NCDHHS will review orders to ensure equitable distribution. Examples of data reviewed include geographic location, doses administered, and current inventory.
- Doses obtained from NCIP are for VFC-eligible patients only. Privately purchased stock must be used for non-eligible patients.
For more information on clesrovimab administration, refer to CDC's Clesrovimab Guidance.
How to contact us
For assistance, contact the NCIP Help Desk by phone at 1.877.USE.NCIR (1-877-873-6247) or by email.
Thank you for your ongoing partnership and dedication to improving immunization outcomes in North Carolina.
In Health,
NC Department of Health and Human Services